Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The Contribution of Obesity and Hyperandrogenemia to the Risk of Metabolic Disturbances of Women with Polycystic Ovary Syndrome Defines the Therapeutic Approach. Clinical Implications

Mardia López-Alarcón
* ORCID logo ,
Víctor Saul Vital-Reyes
,
Eduardo Almeida-Gutiérrez
ORCID logo ,
Jorge Maldonado-Hernández
,
Salvador Flores-Chavez
,
Juan Manuel Dominguez-Salgado
,
Jose Vite-Bautista
,
David Cruz-Martinez
,
Aly S Barradas-Vazquez
,
Ricardo Z´Cruz-Lopez
Version 1 : Received: 4 July 2023 / Approved: 5 July 2023 / Online: 5 July 2023 (07:28:12 CEST)

A peer-reviewed article of this Preprint also exists.

López-Alarcón, M.; Vital-Reyes, V.S.; Almeida-Gutiérrez, E.; Maldonado-Hernández, J.; Flores-Chávez, S.; Domínguez-Salgado, J.M.; Vite-Bautista, J.; Cruz-Martínez, D.; Barradas-Vázquez, A.S.; Z’Cruz-López, R. Obesity and Hyperandrogenemia in Polycystic Ovary Syndrome: Clinical Implications. J. Pers. Med. 2023, 13, 1319. López-Alarcón, M.; Vital-Reyes, V.S.; Almeida-Gutiérrez, E.; Maldonado-Hernández, J.; Flores-Chávez, S.; Domínguez-Salgado, J.M.; Vite-Bautista, J.; Cruz-Martínez, D.; Barradas-Vázquez, A.S.; Z’Cruz-López, R. Obesity and Hyperandrogenemia in Polycystic Ovary Syndrome: Clinical Implications. J. Pers. Med. 2023, 13, 1319.

Abstract

Polycystic ovary syndrome (PCOS) usually comes along with metabolic disturbances attributed to androgen excess and obesity, but the contribution of each has not been defined, and the occurrence of metabolic disturbances is frequently not investigated. We evaluated 99 PCOS and 41 non-PCOS women. Clinical biomarkers of glucose-, liver-, and endothelial-related metabolic alterations were measured; participants were categorized into four groups according with obesity (OB) and hyperandrogenemia (HA) statuses: Healthy (no-HA, lean), HA (HA, lean), OB (no-HA, OB), and HAOB (HA, OB). Metabolic disturbances were highly frequent in PCOS women (70%). BMI correlated with all biomarkers, while free testosterone (FT) only with glucose- and hepatic-related indicators. Despite insulin sensitivity and liver enzymes were associated with FT, women with obesity exhibited lower M [coeff = 8.56 – 0.080(FT) –3.71(Ob); p <0.001)] and higher aspartate aminotransferase (coeff = 26.27 + 0.532(FT) + 8.08(Ob); p = 0.015)] than lean at the same level of FT. Women with obesity exhibited greater risk of metabolic disorders than lean, independently of hyperandrogenemia. Clinicians are compelled to search for metabolic alterations in PCOS women; obesity must be handled in all cases, but hyperandrogenemia needs to be managed also in those with glucose- or liver-related disturbances.

Keywords

keyword 1: Polycystic ovary syndrome; keyword 2: obesity-related metabolic disorders, keyword 3: hyperandrogenemia

Subject

Medicine and Pharmacology, Clinical Medicine

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.